CN117098545A - 阿克汀文变体多肽和相关方法 - Google Patents

阿克汀文变体多肽和相关方法 Download PDF

Info

Publication number
CN117098545A
CN117098545A CN202280015649.3A CN202280015649A CN117098545A CN 117098545 A CN117098545 A CN 117098545A CN 202280015649 A CN202280015649 A CN 202280015649A CN 117098545 A CN117098545 A CN 117098545A
Authority
CN
China
Prior art keywords
polypeptide
gly
ovarian cancer
asn
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280015649.3A
Other languages
English (en)
Chinese (zh)
Inventor
的场伸行
M·登特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Publication of CN117098545A publication Critical patent/CN117098545A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280015649.3A 2021-03-04 2022-03-04 阿克汀文变体多肽和相关方法 Pending CN117098545A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156715P 2021-03-04 2021-03-04
US63/156,715 2021-03-04
PCT/US2022/070961 WO2022187851A1 (en) 2021-03-04 2022-03-04 Actinohivin variant polypeptides and related methods

Publications (1)

Publication Number Publication Date
CN117098545A true CN117098545A (zh) 2023-11-21

Family

ID=83155364

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280015649.3A Pending CN117098545A (zh) 2021-03-04 2022-03-04 阿克汀文变体多肽和相关方法

Country Status (9)

Country Link
US (1) US20240123026A1 (https=)
EP (1) EP4301389A4 (https=)
JP (1) JP2024509385A (https=)
CN (1) CN117098545A (https=)
AU (1) AU2022229597A1 (https=)
CA (1) CA3210629A1 (https=)
IL (1) IL305259A (https=)
MX (1) MX2023010183A (https=)
WO (1) WO2022187851A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12145966B2 (en) 2017-02-10 2024-11-19 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and methods of treatment using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012071492A1 (en) * 2010-11-23 2012-05-31 Georgia Tech Research Corporation Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells
EP3194973A1 (en) * 2014-09-17 2017-07-26 Institut Curie Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor
US12145966B2 (en) * 2017-02-10 2024-11-19 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and methods of treatment using them

Also Published As

Publication number Publication date
EP4301389A1 (en) 2024-01-10
WO2022187851A9 (en) 2022-09-29
MX2023010183A (es) 2023-11-22
WO2022187851A1 (en) 2022-09-09
CA3210629A1 (en) 2022-09-09
EP4301389A4 (en) 2025-03-12
AU2022229597A1 (en) 2023-10-19
IL305259A (en) 2023-10-01
JP2024509385A (ja) 2024-03-01
US20240123026A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
CN110913908B (zh) 靶向msln的三特异性蛋白质及使用方法
JP7126269B2 (ja) Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法
CA2959821C (en) Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
JP2025061682A (ja) 抗ｍｕｃ１６抗体及びその使用
JP6359461B2 (ja) Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤
WO2020041626A1 (en) Affibody proteins specific for b7-h3 (cd276)
EA022415B1 (ru) Биспецифичные молекулы, связывающие egfr/igfir
EP2014302A1 (en) An antibody specific for the Tn antigen for the treatment of cancer
JP2017524033A (ja) がんのチェックポイント干渉療法の成績を高めるための腫瘍抗原特異的抗体およびｔｌｒ３刺激
JP6574257B2 (ja) 新規の抗Ｎｏｄａｌ抗体及びその使用方法
JP2022081519A (ja) Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
CN120092020A (zh) Cnx抗原结合分子
AU2012267710A1 (en) Anti-CD22 antigen binding molecules to treat lung cancer and prostate cancer
CN117098545A (zh) 阿克汀文变体多肽和相关方法
CN119403829A (zh) 对于肿瘤抗原特异性的抗体和cd47抑制剂的组合
JP2025504036A (ja) 親和性が増強された抗ｅｃｍナノボディ－サイトカイン融合体およびその応用
JP2018503645A (ja) 標的への抗癌剤の送達を増加させる方法
CN119345386B (zh) 靶向Claudin18.2的抗体药物耦联物及其用途
US20250288687A1 (en) Combination of antibody-drug conjugates and dnmt inhibitors
US12281171B2 (en) Periostin antibodies and methods of using the same
WO2025088496A1 (en) Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
BR112017019978B1 (pt) Anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, polinucleotídeo, vetor, célula microbiana transgênica ex vivo, método para produzir uma célula transgênica ex vivo, método para produzir um anticorpo, composição farmacêutica e uso do anticorpo
HK40007828A (zh) 人附睾蛋白4(he4)用於评估muc16阳性癌症治疗的响应性的用途
HK1249911B (en) Anti-muc16 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination